35 results
8-K
MOTS
Motus GI Holdings Inc
21 Apr 22
Regulation FD Disclosure
8:05am
. (the “Company”) issued a press release announcing that it had completed enrollment in the European Union Feasibility Study of the Pure-Vu® System, which … , the Company announced that it had completed enrollment in the European Union Feasibility Study of the Pure-Vu® System, which is evaluating the clinical outcomes
8-K
MOTS
Motus GI Holdings Inc
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
. (the “Company”) issued a press release announcing enrollment of patients at a second site in the European Union (EU) study of the Pure-Vu System … Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients with a history of poor bowel preparation using a low volume
8-K
EX-99.1
MOTS
Motus GI Holdings Inc
16 Jun 21
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
8:05am
Exhibit 99.1
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
of the Pure-Vu® System as a New Method for Bowel … associated with the diagnosis and management of gastrointestinal conditions, announced today enrollment of the first patients in the European Union (EU
8-K
EX-99.1
MOTS
Motus GI Holdings Inc
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
Exhibit 99.1
Motus GI Announces Enrollment of Patients at Second Site in the European Union
Outpatient Study of the Pure-Vu® System
FORT … , today announced that GastroZentrum Lippe, one of the top private endoscopy clinics in Germany, has enrolled patients into the European Union (EU
8-K
EX-99.1
MOTS
Motus GI Holdings Inc
21 Apr 22
Regulation FD Disclosure
8:05am
Exhibit 99.1
Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing … that the final patient has been enrolled in the European Union (EU) study of the Pure-Vu System, which is evaluating the clinical outcomes in patients
8-K
61470
16 Jun 21
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
8:05am
8-K
vpaxlcshw2hns v8
24 May 22
Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System
4:10pm
8-K
EX-99.1
f8mlo3 owotk5bodc9
12 May 22
Motus GI Reports First Quarter 2022 Financial Results
4:10pm
8-K
EX-99.1
8zckw7f vfmgfjyu179
12 Aug 21
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
DEF 14A
33ty23e2uqb7mquc
3 May 19
Definitive proxy
7:34am
8-K
EX-10.2
zmwkfzxf
28 Aug 20
Motus GI Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market
4:36pm
S-3
EX-1.2
70ril
26 Mar 19
Shelf registration
4:42pm
8-K
EX-1.1
ogefxf3ucgb6a r7jyve
20 Dec 18
Motus GI Announces Launch of Proposed Follow-on Public Offering
8:02am
8-K
EX-1.1
7m34iqjb9ljyw2
27 Jun 19
Motus GI Announces Proposed Public Offering of Common Stock
8:01am